SEARCH

SEARCH BY CITATION

References

  • 1
    McKinley MJ, Albiston AL, Allen AM et al. The brain renin–angiotensin system: Location and physiological roles. Int. J. Biochem. Cell Biol. 2003; 35: 90118.
  • 2
    Steckelings UM, Unger T. The renin–angiotensin–aldosterone system. In: Mancia G, Grassi G, Kjeldsen SE (eds). Manual of Hypertension of the European Society of Hypertension. Informa Healthcare, London. 2008; 11016.
  • 3
    Unger T. The role of the renin–angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. 2002; 89: A310.
  • 4
    Tian M, Zhu D, Xie W, Shi J. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett. 2012; 586: 373745.
  • 5
    Mertens B, Vanderheyden P, Michotte Y, Sarre S. The role of the central renin–angiotensin system in Parkinson's disease. J. Renin Angiotensin Aldosterone Syst. 2010; 11: 4956.
  • 6
    Mogi M, Iwanami J, Horiuchi M. Roles of brain angiotensin II in cognitive function and dementia. Int. J. Hypertens. 2012; 2012: 169649.
  • 7
    Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J. Mol. Med. 2008; 86: 71522.
  • 8
    De Góis Queiroz AI, Medeiros CD, Ribeiro BMM, de Lucena DF, Macêdo DS. Angiotensin receptor blockers for bipolar disorder. Med. Hypotheses 2013; 80: 25963.
  • 9
    Steckelings UM, Kaschina E, Unger T. The AT2 receptor: A matter of love and hate. Peptides 2005; 26: 14019.
  • 10
    Santos RAS, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: New players of the renin–angiotensin system. J. Endocrinol. 2013; 216: R117.
  • 11
    Ferreira AJ, Santos RAS, Bradford CN et al. Therapeutic implications of the vasoprotective axis of the renin–angiotensin system in cardiovascular diseases. Hypertension 2010; 55: 20713.
  • 12
    Bader M, Santos RA, Unger T, Steckelings UM. New therapeutic pathways in the RAS. J. Renin Angiotensin Aldosterone Syst. 2012; 13: 5058.
  • 13
    Laflamme L, Gasparo M, Gallo JM, Payet MD, Gallo-Payet N. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J. Biol. Chem. 1996; 271: 2272935.
  • 14
    Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 1996; 122: 5967.
  • 15
    Li J-M, Mogi M, Tsukuda K et al. Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor–MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol. Endocrinol. 2007; 21: 499511.
  • 16
    Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol. Endocrinol. 1999; 13: 161526.
  • 17
    Côté F, Laflamme L, Payet MD, Gallo-Payet N. Nitric oxide, a new second messenger involved in the action of angiotensin II on neuronal differentiation of NG108-15 cells. Endocr. Res. 1998; 24: 4037.
  • 18
    Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J. Exp. Med. 1998; 188: 66170.
  • 19
    Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: Role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J. 2003; 17: 20946.
  • 20
    Namsolleck P, Boato F, Schwengel K et al. AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol. Dis. 2013; 51: 17791.
  • 21
    Wan Y, Wallinder C, Plouffe B et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 2004; 47: 59956008.
  • 22
    Anand U, Facer P, Yiangou Y et al. Angiotensin II type 2 receptor (AT(2)R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur. J. Pain. 2013; 17: 101226.
  • 23
    Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain. Comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med. 2013; 14: 692705.
  • 24
    Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 9951003.
  • 25
    Iwai M, Liu H-W, Chen R et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 8438.
  • 26
    Li J, Culman J, Hörtnagl H et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J. 2005; 19: 61719.
  • 27
    McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 2009; 40: 14829.
  • 28
    McCarthy CA, Vinh A, Broughton BRS, Sobey CG, Callaway JK, Widdop RE. Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. Hypertension 2012; 60: 15317.
  • 29
    Lee S, Brait VH, Arumugam TV et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp. Transl. Stroke Med. 2012; 4: 16.
  • 30
    Gelosa P, Pignieri A, Fändriks L et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: Focus on renal damage. J. Hypertens. 2009; 27: 244451.
  • 31
    Shraim N, Mertens B, Clinckers R, Sarre S, Michotte Y, Van Eeckhaut A. Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. J. Neurosci. Methods 2011; 202: 13742.
  • 32
    Zhao M-Z, Nonoguchi N, Ikeda N et al. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J. Cereb. Blood Flow Metab. 2006; 26: 117688.
  • 33
    Shen LH, Li Y, Chen J et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J. Cereb. Blood Flow Metab. 2007; 27: 613.
  • 34
    Iwanami J, Mogi M, Tsukuda K et al. Effect of angiotensin II type 2 receptor deletion in hematopoietic cells on brain ischemia-reperfusion injury. Hypertension 2011; 58: 4049.
  • 35
    Iwanami J, Mogi M, Li J-M et al. Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia–reperfusion brain injury in mice. Stroke 2008; 39: 25549.
  • 36
    López-Aguilera F, Plateo-Pignatari MG, Biaggio V, Ayala C, Seltzer AM. Hypoxic preconditioning induces an AT2-R./VEGFR-2 (Flk-1) interaction in the neonatal brain microvasculature for neuroprotection. Neuroscience 2012; 216: 19.
  • 37
    Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1–7)/Mas pathway in the brain. The axis of good. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011; 300: R80417.
  • 38
    Becker LK, Etelvino GM, Walther T, Santos RAS, Campagnole-Santos MJ. Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. Am. J. Physiol. Heart Circ. Physiol. 2007; 293: H141624.
  • 39
    Mecca AP, Regenhardt RW, O'Connor TE et al. Cerebroprotection by angiotensin-(1–7) in endothelin-1-induced ischaemic stroke. Exp. Physiol. 2011; 96: 108496.
  • 40
    Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 9706.
  • 41
    Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1–7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 699705.
  • 42
    Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J. Biomol. Screen. 2011; 16: 87885.
  • 43
    Sampaio WO, Nascimento AAS, Santos RAS. Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats. Am. J. Physiol. Heart Circ. Physiol. 2003; 284: H198594.
  • 44
    Feterik K, Smith L, Katusic ZS. Angiotensin-(1–7) causes endothelium-dependent relaxation in canine middle cerebral artery. Brain Res. 2000; 873: 7582.
  • 45
    Iadecola C, Anrather J. The immunology of stroke: From mechanisms to translation. Nat. Med. 2011; 17: 796808.
  • 46
    Regenhardt RW, Desland F, Mecca AP et al. Anti-inflammatory effects of angiotensin-(1–7) in ischemic stroke. Neuropharmacology 2013; 71C: 15463.
  • 47
    Jiang T, Gao L, Guo J, Lu J, Wang Y, Zhang Y. Suppressing inflammation by inhibiting the NF-κB pathway contributes to the neuroprotective effect of angiotensin-(1–7) in rats with permanent cerebral ischaemia. Br. J. Pharmacol. 2012; 167: 152032.
  • 48
    Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul. Pept. 1995; 59: 26995.
  • 49
    Zhu YZ, Chimon GN, Zhu YC et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. NeuroReport 2000; 11: 11914.
  • 50
    Vervoort VS, Beachem MA, Edwards PS et al. AGTR2 mutations in X-linked mental retardation. Science 2002; 296: 24013.
  • 51
    Wright JW, Reichert JR, Davis CJ, Harding JW. Neural plasticity and the brain renin–angiotensin system. Neurosci. Biobehav. Rev. 2002; 26: 52952.
  • 52
    Côté F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J. Biol. Chem. 1999; 274: 3168692.
  • 53
    Mogi M, Li J-M, Iwanami J et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 1418.
  • 54
    Maul B, von Bohlen und Halbach O, Becker A et al. Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. J. Mol. Med. 2008; 86: 56371.
  • 55
    Tota S, Hanif K, Kamat PK, Najmi AK, Nath C. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology 2012; 222: 185202.
  • 56
    Faure S, Bureau A, Oudart N, Javellaud J, Fournier A, Achard J-M. Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. J. Hypertens. 2008; 26: 200815.
  • 57
    Jing F, Mogi M, Sakata A et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J. Cereb. Blood Flow Metab. 2012; 32: 24855.
  • 58
    Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 2005; 280: 2145362.
  • 59
    Wang N, Verna L, Chen N-G et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 2002; 277: 3417681.
  • 60
    Klotz L, Sastre M, Kreutz A et al. Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J. Neurochem. 2003; 86: 90716.
  • 61
    Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 2004; 24: 1090817.
  • 62
    Nakamura T, Yamamoto E, Kataoka K et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007; 38: 301622.
  • 63
    Wada K, Nakajima A, Katayama K et al. Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J. Biol. Chem. 2006; 281: 1267381.
  • 64
    Zhao Y, Foryst-Ludwig A, Bruemmer D et al. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J. Neurochem. 2005; 94: 1395401.
  • 65
    Ohshima K, Mogi M, Jing F et al. Direct angiotensin ii type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation. PLoS One 2012; 7: e48387.
  • 66
    Lu J, Zhang Y, Shi J. Effects of intracerebroventricular infusion of angiotensin-(1–7) on bradykinin formation and the kinin receptor expression after focal cerebral ischemia-reperfusion in rats. Brain Res. 2008; 1219: 12735.
  • 67
    Zhang Y, Lu J, Shi J et al. Central administration of angiotensin-(1–7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia/reperfusion in rats. Neuropeptides 2008; 42: 593600.
  • 68
    Hellner K, Walther T, Schubert M, Albrecht D. Angiotensin-(1–7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol. Cell. Neurosci. 2005; 29: 42735.
  • 69
    Lazaroni TLN, Raslan ACS, Fontes WRP et al. Angiotensin-(1–7)/Mas axis integrity is required for the expression of object recognition memory. Neurobiol. Learn. Mem. 2012; 97: 11323.
  • 70
    Platten M, Youssef S, Hur EM et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl Acad. Sci. USA 2009; 106: 1494853.
  • 71
    Stegbauer J, Lee D-H, Seubert S et al. Role of the renin–angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl Acad. Sci. USA 2009; 106: 149427.
  • 72
    Kawajiri M, Mogi M, Higaki N et al. Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis. Mult. Scler. 2009; 15: 2625.
  • 73
    Valero-Esquitino V, Monnet-Tschudi F, Honegger P et al. Direct AT2-receptor stimulation improves neurological outcome in a mouse model of multiple sclerosis. In: Proceedings of the 24th Meeting of the International Society of Hypertension (ISH). 2012; Available from: http://www.ish2012.org/docs/01%20ISH%202012%20Journal%20of%20Hypertension.pdf, (accessed 24 June 2013).
  • 74
    Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc. Res. 2011; 92: 4018.
  • 75
    Rompe F, Artuc M, Hallberg A et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2010; 55: 92431.
  • 76
    Jiang T, Gao L, Shi J, Lu J, Wang Y, Zhang Y. Angiotensin-(1–7) modulates renin–angiotensin system associated with reducing oxidative stress and attenuating neuronal apoptosis in the brain of hypertensive rats. Pharmacol. Res. 2012; 67: 8493.